Millipore Sigma Vibrant Logo

345832 Galectin-3C, Human, Recombinant, E. coli

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
View Products on Sigmaaldrich.com
345832
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
345832-100UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 100 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
      Catalogue Number345832
      Brand Family Calbiochem®
      References
      ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.
      Product Information
      FormLyophilized
      FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      Physicochemical Information
      ContaminantsEndotoxin: ≤ 1 EU/µg protein
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      345832-100UG 04055977214352

      Documentation

      Galectin-3C, Human, Recombinant, E. coli Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Galectin-3C, Human, Recombinant, E. coli Certificados de análisis

      CargoNúmero de lote
      345832

      Referencias bibliográficas

      Visión general referencias
      Hoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision30-June-2008 RFH
      DescriptionRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histiolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
      FormLyophilized
      FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
      Purity≥95% by SDS-PAGE
      ContaminantsEndotoxin: ≤ 1 EU/µg protein
      SolubilitySterile PBS (1 mg/ml)
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
      Toxicity Standard Handling
      ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.